Alembic Pharmaceuticals has officially announced the re-appointment of Mr. Pranav Amin as Managing Director for a five-year term, effective from April 1, 2026. The appointment follows shareholder approval obtained during the company's 15th Annual General Meeting held on August 5, 2025.

Leadership Continuity and Governance

The re-appointment ensures leadership continuity at Alembic Pharmaceuticals, with Mr. Pranav Amin continuing in his role as Managing Director. The position is designated as not liable to retire by rotation, providing stability to the company's executive leadership structure.

Professional Background and Role

Mr. Pranav Amin currently heads the International Business division of Alembic Pharmaceuticals. According to the company's disclosure, he has been instrumental in driving growth in the pharmaceutical sector with a strong vision for innovation and global expansion. Under his leadership, the company has strengthened its presence in international markets while focusing on research, development, and high-quality manufacturing.

The company reports that it has experienced remarkable progress under his guidance, achieving sustained growth in both revenue and profitability. His role encompasses overseeing the company's international operations and strategic expansion initiatives.

Family Connections and Board Structure

The disclosure reveals family relationships within the company's leadership structure. Mr. Chirayu Amin, who serves as Chairman of Alembic Pharmaceuticals, is the father of Mr. Pranav Amin. Additionally, Mr. Shaunak Amin, another Managing Director of the company, is also part of the family leadership team.

Regulatory Compliance

Alembic Pharmaceuticals has confirmed full regulatory compliance regarding the appointment. The company has declared that Mr. Pranav Amin is not debarred from holding the office of Director by virtue of any SEBI order or any other regulatory authority. All required details have been submitted in accordance with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

The appointment represents continuity in the company's leadership structure and reinforces its commitment to sustained growth in both domestic and international pharmaceutical markets.

Alembic Pharmaceuticals Limited has officially appointed Mr. Rajkumar Baheti (DIN: 00332079) as Non-Executive Non-Independent Director, effective April 1, 2026. The appointment follows the successful conclusion of the postal ballot process on March 31, 2026, where shareholders demonstrated overwhelming support for the corporate governance decision.

Official Appointment Confirmation

The company formally communicated the appointment to BSE Limited and National Stock Exchange of India Limited under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The appointment was made based on the recommendation of the Nomination and Remuneration Committee and subsequent Board approval.

Director Profile and Qualifications

Mr. Rajkumar Baheti brings extensive professional expertise to the board. He is a Commerce graduate and fellow member of both the Institute of Chartered Accountants of India and the Institute of Company Secretaries of India. With 44 years of professional experience in finance, he has specialized knowledge in corporate finance, financial governance, regulatory compliance, and complex financial matters.

Overwhelming Shareholder Support

The postal ballot results revealed exceptional shareholder confidence in the appointment decision. Shareholders approved the appointment of Mr. Rajkumar Baheti through an ordinary resolution with remarkable support across all voting categories.

Professional Fees Approval

Shareholders also approved the payment of professional fees to Mr. Rajkumar Baheti through a special resolution, demonstrating even stronger support with 99.83% approval rate.

Governance and Independence

The company has confirmed that Mr. Rajkumar Baheti is not related to any existing Directors or Key Managerial Personnel, ensuring independence in board composition. The appointment strengthens the company's governance framework with his extensive experience in financial matters and regulatory compliance.

Voting Process Details

The postal ballot was conducted entirely through remote e-voting facility provided by National Securities Depository Limited (NSDL) from March 2 to March 31, 2026. S. Samdani, Partner at Samdani Shah and Kabra, Company Secretaries, served as the scrutinizer, ensuring full compliance with Companies Act, 2013 and SEBI regulations.

Company Secretary Manisha Saraf formally communicated the results to stock exchanges, completing all regulatory requirements for the appointment process.